New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.
about
A Review of Melatonin, Its Receptors and DrugsProfile of suvorexant in the management of insomniaProtecting the melatonin rhythm through circadian healthy light exposureElectroacupuncture for insomnia disorder: study protocol for a randomized controlled trial.[The newer sedative-hypnotics].Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.Melatonergic drugs in development.Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countriesMood disorders, circadian rhythms, melatonin and melatonin agonists.Critical appraisal of ramelteon in the treatment of insomnia.Chronobiology of Melatonin beyond the Feedback to the Suprachiasmatic Nucleus-Consequences to Melatonin Dysfunction.Investigational melatonin receptor agonists.Tasimelteon for insomnia.Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling.Pharmacotherapy of insomnia.Cardiovascular effects of melatonin receptor agonists.Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.Synthetic melatoninergic ligands: achievements and prospects.Chronomedicine and type 2 diabetes: shining some light on melatonin.Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers.Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database.Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction
P2860
Q26739890-0CF34286-BB2C-4958-A3F4-BF5A52B128F6Q26773214-B97B96B0-6D76-4D0D-BE3C-6906371CF52EQ28385442-ECFF6C29-2AF4-45B3-9D43-D10F4EB43E62Q30845216-89D69478-16FC-4084-ABD0-913539D182BDQ34143490-72106576-7781-41FC-BC8D-FB4A077210CBQ34304485-C73BB53E-F7CE-42DD-8E3B-F5FE9C87BD6DQ34358480-9368C385-B562-49EB-9D2E-A717CB38BC7AQ34440574-F8B037E7-DDA7-433B-9AD4-7DEE87273508Q36040915-4A65027B-33D2-45CC-A601-2DA014BCB9ACQ36722184-14D38AE4-C433-4714-BC0A-031EA2E403EAQ36748061-02E6CA50-FD48-4665-B3EC-6C46BBCB27B2Q36779840-253DA613-6715-4162-A7E5-D9B3E452AADBQ36790442-96E6CB75-2616-4E10-A875-61A4FE037736Q37735169-DF1B868D-8DDA-4358-9480-ABB6A96D2380Q37872781-5C594129-5CAC-4335-8586-6C0841F6555DQ37950409-468B7B2F-677B-4987-857B-9A0E643A6C9EQ38009370-DA540AEA-0B3A-465E-BC6A-CD0313BF8C2FQ38037124-BE1E1861-1C06-471E-88EC-DEFD081D5AA0Q38247486-BC41B37A-C380-4726-BA9F-42F4DE0346F7Q38457000-37E4021F-CFDD-45F0-98C9-70E7A458B7FBQ39040818-49457F42-5336-4B23-9E4E-D32DA7E3D9F3Q41103172-98957412-0332-4879-BB13-E1033941A7E8Q41449637-E8FAF366-9F1C-4DE0-91A7-9C5D7CEF4F59Q46261270-B0E376CC-B29D-4462-A454-2E94190B8535Q58914961-7D5F5685-51F1-4CA0-B215-1048A09ED31F
P2860
New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New approaches in the manageme ...... hetic melatoninergic agonists.
@en
New approaches in the manageme ...... hetic melatoninergic agonists.
@nl
type
label
New approaches in the manageme ...... hetic melatoninergic agonists.
@en
New approaches in the manageme ...... hetic melatoninergic agonists.
@nl
prefLabel
New approaches in the manageme ...... hetic melatoninergic agonists.
@en
New approaches in the manageme ...... hetic melatoninergic agonists.
@nl
P2860
P356
P1476
New approaches in the manageme ...... hetic melatoninergic agonists.
@en
P2093
Rüdiger Hardeland
P2860
P304
P356
10.2147/NDT.S4234
P407
P577
2009-06-10T00:00:00Z